Abstract: The invention concerns the aglycons of factors A1, A2, A3, A'1, A'2, A'3 of antibiotic A/16686, their corresponding tetrahydroderivatives and mixtures thereof. The aglycons are produced by the selective hydrolysis of antibiotic A/16686 factor A1, A2, A3, A'1, A'2 or A'3. The compounds have antibacterial activity against widely diffused gram positive bacteria and are particularly useful for topical treatment of wound infections and acne.

Abstract: A solid rifapentine hydrohalide useful for anti-bacterial purposes.

Abstract: The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Abstract: The invention concerns tetrahydroderivatives of factors A1, A2, A3, A'1, A'2, A'3 of antibiotic A/16686 and mixtures thereof. The tetrahydroderivatives are produced by hydrogenation of the above mentioned factors, preferably by catalytic hydrogenation.The compounds have antibacterial activity, in particular, against widely diffused gram positive bacteria and are particularly useful for topical treatment of wound infections and acne.

Abstract: The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Abstract: The present invention is directed to carboxylic acid esters of deglucoteicoplanin, i.e. of the aglycon moiety of the antibiotic teicoplanin. The compounds of the invention are conveniently prepared either by deglucoteicoplanin or by any of the glycopeptides of the teicoplanin group, such as teicoplanin itself, one of its components, antibiotic L 17054 and antibiotic L 17046.

Abstract: The present invention is directed to ester derivatives at the carboxylic function of the glycopeptidic antibiotic substance called antibiotic L 17046 with antimicrobial activity mainly against gram-positive bacteria.

Abstract: Process for preparing antibiotic L, 17392 by catalytically hydrogenating a deglucoteicoplanin ester of formula ##STR1## wherein A, B and Z represent hydrogen atoms, R represents benzyl or substituted benzyl, wherein the phenyl group is substituted with at least a substituent selected from chloro, bromo, fluoro, nitro, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy and the like, with the exclusion of the tri-nitro phenyl group, or acid addition salts thereof, to catalytic hydrogenolysis in the presence of a poisoned hydrogenation catalyst at a temperature from 10.degree. C. to 40.degree. C. and a pressure between ambient pressure and 5 atm, in an inert organic solvent preferably in the presence of a mineral acid.

Abstract: The present invention concerns new 2'-substituted-4-deoxy-thiazolo[5,4-c]rifamycin SV derivatives having antibacterial activity.These compounds are compounds obtained by chemical modification of thiazolo[5,4-c]rifamycin SV.

Abstract: The present invention refers to a process for transforming teicoplanin factor A.sub.2 component 1 into teicoplanin factor A.sub.2 component 3 by means of a chemical reaction which includes the catalytical hydrogenation of the substrate.

Abstract: The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L 17046. This antibiotic substance is obtained from the known antibiotic substance called teicoplanin (formerly teichomycin) by chemical treatment. The new compound possesses antimicrobial activity expecially against gram-positive bacteria.

Abstract: This invention relates to a process for converting a teicoplanin-like compound into antibiotic L 17046 characterized in that a teicoplanin-like compound selected from teicoplanin complex, any further purified preparation thereof, teicoplanin factor A.sub.2, teicoplanin factor A.sub.3, each of the main components of teicoplanin factor A.sub.2, antibiotic L 17054 and a mixture of two or more of the above substances in any proportion is submitted to hydrolysis with a strong acid in the presence of a polar aprotic organic solvent selected from ethers, ketones and mixtures thereof that a room temperature are liquid.

Abstract: The present invention is directed to a class of basic monocarboxyamide derivatives of actagardine. Actagardine (INN) is an antibiotic substance produced by actinoplanes strains such as Actinoplanes Sp. ATCC 31048 and Actinoplanes Sp. ATCC 31049 which are described in U.S. Pat. No. 4,022,884. Actagardine shows antimicrobial in vitro and in vivo activity against gram-positive organisms. Its complete chemical structure is not yet known but there is only information on its chemical functions and main fragments. In particular, it has been found that actagardine has two carboxylic functions and a primary amino function and can therefore be represented as follows: ##STR1## The compounds of the invention are monoamide derivatives at one of the carboxy functions of actagardine.

Abstract: The present invention is directed to ester derivatives at the carboxylic function of the glycopeptidic antibiotic substance called antibiotic L 17046 with antimicrobial activity mainly against gram-positive bacteria.

Abstract: The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L 17046. This antibiotic substance is obtained from the known antibiotic substance called teicoplanin (formerly teichomycin) by chemical treatment. The new compound possesses antimicrobial activity especially against gram-positive bacteria.

Abstract: The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Abstract: The present invention is directed to a chemical process for preparing antibiotic L 17392 (deglucoteicoplanin) and its salts with bases and acids by submitting a teicoplanin compound or a teicoplanin-like compound to controlled strong acidic hydrolysis conditions.

Abstract: The present invention is directed to a chemical process for preparing the antibiotic substance denominated antibiotic L 17054 and its pharmaceutically acceptable salts by selectively hydrolyzing teicoplanin or a factor or component thereof with a concentrated strong organic acid.

Abstract: The present invention is directed to new water soluble rifampicin derivatives which are suitable for preparing aqueous solutions for oral or parenteral administration. The new derivatives of the invention are 4 and/or 8 alkanoyl or alkanoyloxyalkyl esters of rifampicin and possess essentially the same antibacterial activity of this widely known antibiotic substance.

Abstract: The present invention refers to a chlorine containing antibiotic substance, named antibiotic A/16686 factor A.sub.2, in an essentially pure form. The invention also relates to the process for the production of antibiotic A/16686 factors A.sub.2 by cultivation of an Actinoplanes strain and to the co-produced antibiotic A/16686 factos A.sub.1 and A.sub.3. Antibiotic A/16686 factors A.sub.1, A.sub.2 and A.sub.3 as well as the corresponding non-toxic physiologically acceptable acid addition salts are antimicrobial agents particularly active against gram-positive bacteria.